Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company provides educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides distance learning residency preparatory courses; and develops and sells digital and printed medical content. As of December 31, 2020, it operated a network of 24 undergraduate and graduate medical school campuses consisted of 19 operating units and five approved units. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
IPO Year: 2019
Exchange: NASDAQ
Website: afya.com.br
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2024 | $19.50 | Neutral | UBS |
| 1/29/2024 | $23.00 | Neutral | Citigroup |
| 1/22/2024 | $20.50 → $23.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/13/2023 | $16.50 → $20.50 | Equal-Weight → Overweight | Morgan Stanley |
| 4/8/2022 | $18.00 → $19.00 | Neutral → Outperform | Credit Suisse |
| 3/7/2022 | $27.00 → $21.00 | Buy | UBS |
| 7/21/2021 | $28.50 | Overweight → Equal-Weight | Morgan Stanley |
Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Expressive Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and nine-month periods ended September 30, 2024 (third quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2024 Highlights 3Q24 Net Revenue increased 16.3% YoY to R$841.2 million. Net Revenue excluding acquisitions grew 11.8%, reaching R$808.8 million. 3Q24 Ad
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it will report third-quarter and nine months 2024 financial results for the period ended September 30th, 2024, following the close of the market on Wednesday, November 13th, 2024 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at: https://ir.afya.com.br/financials/quarterly-earnings/ To participate in Afya's Third Quarter and Nine Months 2024 conference call, please follow
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, today announced that it will host its Afya Day on October 29th, 2024. The event will be held in a hybrid format, combining both in-person and online participation, and will feature presentations from Afya's executive team, covering the Company's growth, business strategy and future outlook. Event Details: Date: October 29th, 2024. Time: 9:00 a.m. to 12:00 p.m. (São Paulo time) & 8:00 a.m. to 11:00 a.m. (EST). Format: Hybrid (in-person and virtual participation) Location for in-person attendees: Afya's São Paulo Flagship, Alameda Lore
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced a public commitment to achieve 5 million free health consultations by 2030, in line with Sustainable Development Goal 3 (SDG 3), which aims to ensure healthy lives and promote well-being for all people, at all ages. To serve the communities and achieve the estimated results, Afya intends to increase to 27 the number of its own outpatient clinics that carry out medical consultations and health care in various specialties, such as psychology, physiotherapy, dentistry, among others. Currently, there are 20 outpatient clinics in di
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, today announced that following the conclusion of an administrative procedure, the Ministry of Education ("MEC"), has granted the request for reconsideration submitted by Universidade do Grande Rio Professor José de Souza Herdy ("Unigranrio"). Per the e-MEC portal, Unigranrio reestablished 10 medical seats in the city of Rio de Janeiro, reaching 318 medical seats across both Unigranrio campuses, contributing to Afya's 3,593 total approved medical seats. This seat reconsideration highlights our dedication to excellence in medical educatio
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil announced today that its wholly-owned subsidiary, Afya Participações S.A., has received the total disbursement of BRL500.0 million under the loan agreement with International Finance Corporation ("IFC") to support the Company's expansion program. The financing is IFC's first sustainability-linked loan based on social targets in the education sector. The pricing of IFC's loan will be linked to Afya reaching performance target levels in selected social key performance indicators encompassing free medical consultations for the community and
Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and six-month period, which ended on June 30, 2024 (second quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second Quarter 2024 Highlights 2Q24 Net Revenue increased 13.7% YoY to R$809.9 million. 2Q24 Adjusted EBITDA increased 28.2% YoY reaching R$343.8 million, with an Adjus
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil announced today that its wholly-owned subsidiary, Afya Participações S.A., entered into a loan agreement with International Finance Corporation ("IFC") to finance its expansion program, through acquisitions. The financing is IFC's first sustainability-linked loan based on social targets in the education sector. The pricing of IFC's loan will be linked to Afya reaching performance target levels in selected social key performance indicators encompassing free medical consultations for the community and quality of education according to Braz
Afya Limited (NASDAQ:AFYA, B3: A2FY34))), the leading medical education group and medical practice solutions provider in Brazil, announces the release of its 2023 Sustainability Report. The document, which presents Afya's trajectory throughout 2023, follows the Global Reporting Initiative (GRI) standards and is aligned with the Sustainable Development Goals (SDGs). It also reports specific indicators from the Sustainability Accounting Standards Board (SASB) and elements of the International Integrated Reporting Council (IIRC). The sustainability report contains some of the results of the fourth Greenhouse Gas (GHG) Emissions Inventory. Both of which have undergone individual audits by KPM
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, today announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education ("MEC") authorized the increase of 80 medical seats of Centro Universitário de Maceió (UNIMA Alagoas), in the city of Maceió, located in the state of Alagoas, which will result in an additional payment of R$ 1.25 million per increased seat approval updated by IPCA since 2nd January 2023 until the payment date. With this authorization, Afya has now reached a total of 220 medical seats at UNIMA Alagoas, contributing to the 3,5
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Expressive Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and nine-month periods ended September 30, 2024 (third quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2024 Highlights 3Q24 Net Revenue increased 16.3% YoY to R$841.2 million. Net Revenue excluding acquisitions grew 11.8%, reaching R$808.8 million. 3Q24 Ad
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it will report third-quarter and nine months 2024 financial results for the period ended September 30th, 2024, following the close of the market on Wednesday, November 13th, 2024 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at: https://ir.afya.com.br/financials/quarterly-earnings/ To participate in Afya's Third Quarter and Nine Months 2024 conference call, please follow
Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and six-month period, which ended on June 30, 2024 (second quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second Quarter 2024 Highlights 2Q24 Net Revenue increased 13.7% YoY to R$809.9 million. 2Q24 Adjusted EBITDA increased 28.2% YoY reaching R$343.8 million, with an Adjus
Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three-month period ended March 31, 2024 (first quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). First Quarter 2024 Highlights 1Q24 Net Revenue increased 13.3% YoY to R$804.2 million. 1Q24 Adjusted EBITDA increased 20.5% YoY reaching R$397.9 million, with an Adjusted EBITDA Margin of
Another Year of Strong Performance Robust EPS Expansion Guidance Achievement Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the fourth quarter and full-year period ended December 31, 2023. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2023 Highlights 4Q23 Adjusted Net Revenue increased 22.6% YoY to R$729.5 million. Adjusted Net Revenue excluding acquisitions grew 12.5% to R$669.7 million. 4Q23 Adjusted EBITDA increased 1
Guidance on Track Strong Cash Conversion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the three and nine-month period ended September 30, 2023. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2023 Highlights 3Q23 Adjusted Net Revenue increased 24.6% YoY to R$723.0 million. Adjusted Net Revenue excluding acquisitions grew 13.6%, reaching R$659.0 million. 3Q23 Adjusted EBITDA increased 21.7% YoY, reaching R$278.4 million, w
Afya Limited, or "Afya" (NASDAQ:AFYA, B3: A2FY34))) announced today that will report third-quarter and nine months 2023 financial results for the period ended September 30th, 2023, following the close of the market on Monday, November 13th, 2023 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.afya.com.br/. To participate in Afya's Third Quarter and Nine Months 2023 conference call, please follow the instructions below: Webcast: https://afya.zoom.us/j/97410751315 Dial-in: Brazil: +55 11 4632 2236 or +55 11 4632 2237 or +55 11
High and Predictable Growth Strong Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the three and six-month period ended June 30, 2023. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second Quarter 2023 Highlights 2Q23 Adjusted Net Revenue increased 23.6% YoY to R$712.2 million. Adjusted Net Revenue excluding acquisitions grew 13.5%, reaching R$654.0 million. 2Q23 Adjusted EBITDA increased 21.8% YoY, reaching R$268.2 milli
Afya Limited, or "Afya" (NASDAQ:AFYA) announced today that it will report second-quarter and first half 2023 financial results for the period ended June 30, 2023, following the close of the market on Monday, August 28, 2023 and will host a corresponding conference call and webcast at 05:00 pm EDT. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.afya.com.br/. To participate in Afya's Second Quarter and First Half 2023 conference call, please follow the instructions below: Webcast: https://afya.zoom.us/j/98725139496 Dial-in: Brazil: +55 21 3958 7888 or +55 11 4632 2236 or +55 11 4632 2237 or +55 11 46
High and Predictable Growth Full Year 2023 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA) ("Afya" or the "Company"), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the three-month period ended March 31, 2023 (first quarter 2023). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). First Quarter 2023 Highlights 1Q23 Adjusted Net Revenue increased 25.0% YoY to R$709.4 million. Adjusted Net Revenue excluding acquisitions grew 13.5%, reaching R$644.3 million. 1Q23 Adjusted EBITDA increased 21.9% YoY reaching R
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today announces that its clinical decision software, WhiteBook, an app created by PEBMED, was ranked as one of the 10 Top Apps in Brazil by consumer spend in 2020 for the fifth year in a row. App Annie conducted the study, a website specialized in app analytics and app market data that combined data from iOS and Google Play that evaluates more than 8 million mobile app per year. In the top ten WhiteBook was among great apps such as Tinder, YouTube, Netflix, TikTok and others. Whitebook is a mobile and web application software that helps doctors and medical students to make
SCHEDULE 13G - Afya Ltd (0001771007) (Subject)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
UBS initiated coverage of Afya with a rating of Neutral and set a new price target of $19.50
Citigroup initiated coverage of Afya with a rating of Neutral and set a new price target of $23.00
Morgan Stanley downgraded Afya from Overweight to Equal-Weight and set a new price target of $23.00 from $20.50 previously
Morgan Stanley upgraded Afya from Equal-Weight to Overweight and set a new price target of $20.50 from $16.50 previously
Credit Suisse upgraded Afya from Neutral to Outperform and set a new price target of $19.00 from $18.00 previously
UBS reiterated coverage of Afya with a rating of Buy and set a new price target of $21.00 from $27.00 previously
Morgan Stanley downgraded Afya from Overweight to Equal-Weight and set a new price target of $28.50
UBS upgraded Afya from Neutral to Buy
JP Morgan upgraded Afya from Neutral to Overweight and set a new price target of $34.00
Morgan Stanley analyst Mauricio Cepeda maintains Afya (NASDAQ:AFYA) with a Equal-Weight and lowers the price target from $21 to $19.
Afya (NASDAQ:AFYA) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.45 by 22.22 percent. This is a 61.76 percent increase over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $162.47 million which beat the analyst consensus estimate of $156.68 million by 3.70 percent. This is a 18.90 percent increase over sales of $136.65 million the same period last year.
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and digital health services provider in Brazil, announced today that it has entered into a share purchase agreement for the acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of Unidom Participações S.A. ("Unidompedro" and "Faculdade Dom Luiz"), present in Salvador (BA), Luis Eduardo Magalhães (BA), Barreiras (BA) and Ribeira do Pombal (BA).The acquisition will add 300 operational medical school seats to Afya in Salvador, one of Brazil's largest cities. The authorization request for these 300 seats was made to the Ministry of Educat
Gainers Fitell (NASDAQ:FTEL) shares moved upwards by 20.3% to $2.19 during Monday's regular session. The company's market cap stands at $24.3 million. Vroom (NASDAQ:VRM) stock increased by 20.3% to $0.53. The market value of their outstanding shares is at $75.6 million. Fisker (NYSE:FSR) shares moved upwards by 18.19% to $0.93. The company's market cap stands at $326.9 million. Genius Gr (AMEX:GNS) stock increased by 16.32% to $0.34. The company's market cap stands at $33.0 million. 2U (NASDAQ:TWOU) shares moved upwards by 15.75% to $0.87. The market value of their outstanding shares is at $71.6 million. Mondee Hldgs (NASDAQ:MOND) stock increased by 12.67% to $2.58. The company's marke
Morgan Stanley analyst Javier Martinez downgrades Afya (NASDAQ:AFYA) from Overweight to Equal-Weight and raises the price target from $20.5 to $23.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised Synopsys, Inc. (NASDAQ:SNPS) price target from $540 to $600. Keybanc analyst Jason Celino maintained an Overweight rating. Synopsys shares rose 0.3% to close at $542.69 on Friday. See how other analysts view this stock. Berenberg cut the price target for Corteva, Inc. (NYSE:CTVA) from $63 to $52. Berenberg analyst Aron Ceccarelli downgraded the stock from Buy to Hold. Corteva shares rose 0.7% to close at $46.67 on Friday. See how other analysts view this stock. UBS increased the pr
JP Morgan analyst Marcelo Santos downgrades Afya (NASDAQ:AFYA) from Overweight to Neutral and raises the price target from $22 to $23.
Afya (NASDAQ:AFYA) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.27 by 3.7 percent. This is a 16.67 percent increase over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $148.23 million which beat the analyst consensus estimate of $140.74 million by 5.32 percent. This is a 33.74 percent increase over sales of $110.83 million the same period last year.